{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:01:25Z","timestamp":1781272885505,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aggressive and diverse subtype of breast cancer known as triple-negative breast cancer (TNBC) has poor clinical outcomes and few specific therapeutic choices. Tumor-infiltrating lymphocytes (TILs), T-cell receptor-engineered T cells, and chimeric antigen receptor T (CAR-T) cells are examples of adoptive cell therapy (ACT), which has become a promising immunotherapeutic approach. Its clinical application in TNBC is still difficult, nevertheless. This study used bibliometric techniques to thoroughly assess growing hotspots, intellectual structure, and worldwide research trends pertaining to ACT in TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Scopus database was searched for publications related to ACT in TNBC from 2011 to 2025. There were only original articles and reviews written in English. VOSviewer (version 1.6.20) and Microsoft Excel 2021 were used to analyse bibliometric indicators, such as annual publication output, country and institutional contributions, authorship patterns, citation characteristics, and keyword co-occurrence. To investigate thematic evolution and collaboration patterns, network visualisation and clustering analysis were carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a compound annual growth rate of more than 60%, a total of 8,496 publications were found, indicating an exponential rise in research output, especially beyond 2020. Together, China and the US accounted for over 60% of all publications, dominating the world\u2019s research output. The core research network was made up of a few institutions and very productive writers. CAR-T cell therapy, tumor microenvironment manipulation, immunological checkpoint inhibition, metabolic reprogramming, and biomarker-driven methods were among the clinically orientated themes that emerged from foundational and preclinical investigations, according to keyword analysis. The literature shows ongoing translational difficulties with regard to tumor heterogeneity, antigen instability, immunosuppressive microenvironments, and safety concerns in solid tumors, despite increased research activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over the past ten years, research on ACT in TNBC has grown significantly, reflecting both unmet clinical need and growing scientific interest. However, continuous efforts to overcome biological and translational constraints are highlighted by the concentration of scientific leadership and the conceptual move towards combination methods and next-generation engineering approaches. This bibliometric analysis offers a thorough picture of the state of the field and could direct future research, teamwork, and the creation of more potent ACT tactics for TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05277-6","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:12:50Z","timestamp":1781079170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bibliometric analysis of global research trends in adoptive cell therapy for triple negative breast cancer over the past 15 years"],"prefix":"10.1007","volume":"17","author":[{"given":"Wesam Ibrahim Abo","family":"Elenien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Ashraf","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef Abo","family":"Elenien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momen","family":"Heiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Abouelenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunya Abbas","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan Khaleel","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"3","key":"5277_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jncc.2025.02.002","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, Liu X, Duan H, Feng Z, Liu Y, Zhang Y, Lyu Z, Song F, Song F, Yang L, Liu H, Huang Y. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025;5(3):287\u201396. https:\/\/doi.org\/10.1016\/j.jncc.2025.02.002.","journal-title":"J Natl Cancer Cent"},{"key":"5277_CR2","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.adcanc.2023.100090","volume":"7","author":"A Dey","year":"2023","unstructured":"Dey A, Ghosh S, Jha S, Hazra S, Srivastava N, Chakraborty U, Roy AG. Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. Adv Cancer Biology - Metastasis. 2023;7:100090. https:\/\/doi.org\/10.1016\/j.adcanc.2023.100090.","journal-title":"Adv Cancer Biology - Metastasis"},{"issue":"1","key":"5277_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13578-025-01359-0","volume":"15","author":"Z Chen","year":"2025","unstructured":"Chen Z, Liu Y, Lyu M, Chan CH, Sun M, Yang X, Qiao S, Chen Z, Yu S, Ren M, Lu A, Zhang G, Li F, Yu Y. Classifications of triple-negative breast cancer: insights and current therapeutic approaches. Cell Bioscience. 2025;15(1):13. https:\/\/doi.org\/10.1186\/s13578-025-01359-0.","journal-title":"Cell Bioscience"},{"key":"5277_CR4","doi-asserted-by":"publisher","first-page":"689553","DOI":"10.3389\/fonc.2021.689553","volume":"11","author":"K-J Hao","year":"2021","unstructured":"Hao K-J, Jia X, Dai W-T, Huo Z-M, Zhang H-Q, Liu J-W, Wang X-B. Mapping intellectual structures and research hotspots of triple negative breast cancer: A bibliometric analysis. Front Oncol. 2021;11:689553. https:\/\/doi.org\/10.3389\/fonc.2021.689553.","journal-title":"Front Oncol"},{"issue":"15","key":"5277_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153801","volume":"15","author":"L Morrison","year":"2023","unstructured":"Morrison L, Okines A. Systemic therapy for metastatic triple negative breast cancer: current treatments and future directions. Cancers. 2023;15(15):3801. https:\/\/doi.org\/10.3390\/cancers15153801.","journal-title":"Cancers"},{"issue":"7","key":"5277_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796. https:\/\/doi.org\/10.3390\/pharmaceutics15071796.","journal-title":"Pharmaceutics"},{"key":"5277_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/BCTT.S516542","volume":"17","author":"H Jie","year":"2025","unstructured":"Jie H, Ma W, Huang C. Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review. Breast Cancer (Dove Med Press). 2025;17:265\u201374. https:\/\/doi.org\/10.2147\/BCTT.S516542.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"5277_CR8","doi-asserted-by":"publisher","first-page":"1194020","DOI":"10.3389\/fimmu.2023.1194020","volume":"14","author":"R Li","year":"2023","unstructured":"Li R, Cao L. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy. Front Immunol. 2023;14:1194020. https:\/\/doi.org\/10.3389\/fimmu.2023.1194020.","journal-title":"Front Immunol"},{"key":"5277_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285\u201396. https:\/\/doi.org\/10.1016\/j.jbusres.2021.04.070.","journal-title":"J Bus Res"},{"key":"5277_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-981-97-6818-9_8","volume-title":"Nutrition and stroke: current state and future perspectives","author":"WI Abo-Elenien","year":"2024","unstructured":"Abo-Elenien WI, Mohamed W. Exploring the Relationship Among Stroke, Hypertension, and Hyperlipidemia: A 10-Year Bibliometric Analysis. In: Mohamed W, Mat-Nor MB, editors. Nutrition and stroke: current state and future perspectives. Springer Nature Singapore; 2024. p. 175\u2013210. https:\/\/doi.org\/10.1007\/978-981-97-6818-9_8."},{"issue":"1","key":"5277_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s43042-024-00611-5","volume":"25","author":"WI Abo- Elenien","year":"2024","unstructured":"Abo- Elenien WI, Badawy SG, Abouelenin O, Hussein FK, Kumari S. Role of sgk1 in cancer: a bibliometric analysis from 2013 to 2023\u2014review article. Egypt J Med Hum Genet. 2024;25(1):142. https:\/\/doi.org\/10.1186\/s43042-024-00611-5.","journal-title":"Egypt J Med Hum Genet"},{"issue":"8","key":"5277_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011623","volume":"6","author":"Q-H Pu","year":"2016","unstructured":"Pu Q-H, Lyu Q-J, Su H-Y. Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015. BMJ Open. 2016;6(8):e011623. https:\/\/doi.org\/10.1136\/bmjopen-2016-011623.","journal-title":"BMJ Open"},{"issue":"3","key":"5277_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0536.2008.01405.x","volume":"59","author":"DR Smith","year":"2008","unstructured":"Smith DR. Bibliometrics, dermatology and contact dermatitis. Contact Dermatitis. 2008;59(3):133\u20136. https:\/\/doi.org\/10.1111\/j.1600-0536.2008.01405.x.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"5277_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ Van Eck","year":"2010","unstructured":"Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338. https:\/\/doi.org\/10.1007\/s11192-009-0146-3.","journal-title":"Scientometrics"},{"issue":"17","key":"5277_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","volume":"17","author":"S Rafii","year":"2025","unstructured":"Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, et al. Advancing CAR T-Cell therapy in solid tumors: current landscape and future directions. Cancers. 2025;17(17):2898. https:\/\/doi.org\/10.3390\/cancers17172898.","journal-title":"Cancers"},{"issue":"4","key":"5277_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40291-023-00652-3","volume":"27","author":"I O\u2019Connell","year":"2023","unstructured":"O\u2019Connell I, Dongre A. Immune checkpoint blockade therapy for breast cancer: lessons from epithelial-mesenchymal transition. Mol Diagn Ther. 2023;27(4):433\u201344. https:\/\/doi.org\/10.1007\/s40291-023-00652-3.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"5277_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13058-025-02119-1","volume":"27","author":"H-C Lien","year":"2025","unstructured":"Lien H-C, Li Y-C, Huang Y-J, Chen K-C, Chen T-W, Chen I-C, et al. Carcinomas exhibiting epithelial-mesenchymal transition manifest an M2 macrophage-enriched tumor immune microenvironment. Breast Cancer Res. 2025;27(1):177. https:\/\/doi.org\/10.1186\/s13058-025-02119-1.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"5277_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41417-025-00931-7","volume":"32","author":"Z Tu","year":"2025","unstructured":"Tu Z, Chen Y, Zhang Z, Meng W, Li L. Barriers and solutions for CAR-T therapy in solid tumors. Cancer Gene Ther. 2025;32(9):923\u201334. https:\/\/doi.org\/10.1038\/s41417-025-00931-7.","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"5277_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212223","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang J, He Y, Hu F, Hu C, Sun Y, Yang K, et al. Metabolic reprogramming of immune cells in the tumor microenvironment. Int J Mol Sci. 2024;25(22):12223. https:\/\/doi.org\/10.3390\/ijms252212223.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5277_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17121520","volume":"17","author":"AW Song","year":"2025","unstructured":"Song AW, Song X. Rewiring T cell metabolism to enhance CAR T cell function in solid tumor microenvironments. Pharmaceutics. 2025;17(12):1520. https:\/\/doi.org\/10.3390\/pharmaceutics17121520.","journal-title":"Pharmaceutics"},{"issue":"1","key":"5277_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-024-01981-5","volume":"23","author":"Q Dang","year":"2024","unstructured":"Dang Q, Li B, Jin B, Ye Z, Lou X, Wang T, Wang Y, Pan X, Hu Q, Li Z, Ji S, Zhou C, Yu X, Qin Y, Xu X. Cancer immunometabolism: advent, challenges, and perspective. Mol Cancer. 2024;23(1):72. https:\/\/doi.org\/10.1186\/s12943-024-01981-5.","journal-title":"Mol Cancer"},{"issue":"1","key":"5277_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Translational Med. 2024;22(1):897. https:\/\/doi.org\/10.1186\/s12967-024-05703-9.","journal-title":"J Translational Med"},{"issue":"1","key":"5277_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22(1):141. https:\/\/doi.org\/10.1186\/s12943-023-01844-5.","journal-title":"Mol Cancer"},{"issue":"1","key":"5277_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00534-0","volume":"11","author":"Z Pang","year":"2023","unstructured":"Pang Z, Lu M-M, Zhang Y, Gao Y, Bai J-J, Gu J-Y, et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11(1):104. https:\/\/doi.org\/10.1186\/s40364-023-00534-0.","journal-title":"Biomark Res"},{"key":"5277_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.799206","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Cao W, Wang F, Xie X, Li Y, et al. Single-cell analysis of target antigens of CAR-T reveals a potential landscape of \u201con-target, off-tumor toxicity.\u201d Front Immunol. 2021;12:799206. https:\/\/doi.org\/10.3389\/fimmu.2021.799206.","journal-title":"Front Immunol"},{"issue":"5","key":"5277_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/genes14051008","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Liu X, Chang C-Y, Wang HY, Wang R-F. The interplay between T cells and cancer: the basis of immunotherapy. Genes. 2023;14(5):1008. https:\/\/doi.org\/10.3390\/genes14051008.","journal-title":"Genes"},{"issue":"8","key":"5277_CR27","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley CC, Zehn D, Gottschalk S, Chi H. T cell dysfunction and therapeutic intervention in cancer. Nat Immunol. 2024;25(8):1344\u201354. https:\/\/doi.org\/10.1038\/s41590-024-01896-9.","journal-title":"Nat Immunol"},{"issue":"12","key":"5277_CR28","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2017;23(12):3061\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2083.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5277_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"AD Posey","year":"2024","unstructured":"Posey AD, Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10(8):687\u201395. https:\/\/doi.org\/10.1016\/j.trecan.2024.05.007.","journal-title":"Trends Cancer"},{"issue":"1","key":"5277_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00783-1","volume":"13","author":"S Saeidpour Masouleh","year":"2025","unstructured":"Saeidpour Masouleh S, Nasiri K, Ostovar Ravari A, Saligheh Rad M, Kiani K, Sharifi Sultani A, et al. Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. Biomark Res. 2025;13(1):69. https:\/\/doi.org\/10.1186\/s40364-025-00783-1.","journal-title":"Biomark Res"},{"issue":"3","key":"5277_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/path.6395","volume":"265","author":"X Lu","year":"2025","unstructured":"Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, et al. Extracellular matrix cancer-associated fibroblasts promote stromal fibrosis and immune exclusion in triple-negative breast cancer. J Pathol. 2025;265(3):385\u201399. https:\/\/doi.org\/10.1002\/path.6395.","journal-title":"J Pathol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05277-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:38:20Z","timestamp":1781271500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05277-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5277"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05277-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a bibliometric analysis of existing literature and does not involve any studies with human participants or animals performed by any of the authors. The data were retrieved from the Scopus database and did not require institutional ethical clearance. Not applicable. This research did not involve human subjects, and no individual participant data were collected or used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"896"}}